In the pharmaceutical industry, Methyldopa 500 mg is a foundational centrally-acting antihypertensive, particularly recognized as the “Gold Standard” for managing hypertension during pregnancy.

As a pharmacist and manufacturer, I can confirm that a dosage of 500 mg three times a day (TID) is within the standard therapeutic range for adults, though it requires careful clinical oversight.

Clinical Dosage and Limits

For your B2B marketplace and technical guides, it is essential to note how this dose fits into the global treatment protocols:

• Standard Range: The usual adult maintenance dose is 500 mg to 2,000 mg daily, divided into 2 to 4 doses.

• Your Dose (1,500 mg/day): Taking 500 mg three times a day totals 1,500 mg daily. This is a common moderate-to-high dose used when lower doses (like 250 mg TID) are insufficient to reach target blood pressure.

• Maximum Limit: The absolute maximum recommended dose for adults is 3,000 mg daily.

Mechanism: The Alpha-2 Receptor Agonism

Methyldopa works in the brain rather than directly on the blood vessels, making it unique among many other blood pressure medications.

Conversion: Methyldopa is a prodrug. Once it crosses the blood-brain barrier, it is converted into alpha-methylnorepinephrine.

Agonism: It stimulates the central alpha-2 adrenergic receptors.

Sympathetic Outflow: This stimulation tells the brain to reduce the “sympathetic outflow”—the signals that usually tell the heart to beat faster and blood vessels to constrict.

Result: Blood pressure drops because the heart rate and peripheral vascular resistance are lowered.

The Pharmacist’s “Technical Warning”

As you promote your firm on digital platforms, providing these safety nuances is essential for professional authority:

• The “Sedation” Effect: Because it works in the brain, Methyldopa often makes patients feel very sleepy or drowsy, especially during the first few days of a dose increase.

• Coombs Test: About 10–20% of patients on long-term Methyldopa therapy may develop a positive direct Coombs test, which can occasionally lead to hemolytic anemia.

• Liver Function: It can rarely cause “drug-induced hepatitis.” Baseline and periodic liver function tests (LFTs) are highly recommended.

• Abrupt Withdrawal: Patients should never stop this dose suddenly, as it can cause a “rebound” spike in blood pressure.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai:

• The “Maternal Health” USP: On your marketplace, position Methyldopa as the primary choice for Pregnancy-Induced Hypertension (PIH) and Preeclampsia. This is a massive, consistent market for international health tenders.

• Stability for Export: Methyldopa is stable but can darken if exposed to air and light. Utilizing Alu-Alu blister packaging ensures a 36-month shelf life, vital for export to Zone IVb tropical regions.

• Content Uniformity: At a 500 mg dose, ensuring precise content uniformity is critical. Highlighting your WHO-GMP quality control processes will attract high-value B2B buyers.

• Dossier Support: We provide full CTD/eCTD Dossiers to support your firm’s registration in international markets.